Presentation: Effect of Nizatidine, a H2 Receptor Antagonist on the Xerostomia in Patients with Sjögren's Syndrome (2007)

1096 Effect of Nizatidine, a H2 Receptor Antagonist on the Xerostomia in Patients with Sjögren's Syndrome

BACKGROUND and PURPOSE: In Sjogren's syndrome (SS), oral dryness (xerostomia) is frequently the most bothersome symptom and is sufficient to have a significant negative effect on quality of life. Chronic atrophic gastritis is also a common finding in SS and is often associated with superficial gastritis and high pepsinogen I levels. One would expect that administration of a H2 histamine receptor blocking drug would be an appropriate approach to treating SS patients with superficial gastritis. The aim of the present study was to assess the efficacy of nizatidine, a H2 receptor antagonist, in the treatment of xerostomia in patients with SS.
Methods: A total of 22 patients with primary SS and 17 with secondary SS patients were included in the study. All patients fulfilled the new American-European Consensus Group criteria for SS and were randomly assigned to receive nizatidine (n=24, 150 mg twice a day) or famotidine (n=15, 20 mg twice a day) as a control, and were followed up for 8 weeks. The patients were evaluated prior to (baseline) and then after 4 and 8 weeks of therapy. Throughout the study, the patients were asked for both subjective and objective assessments of oral dryness using a visual analog scale (VAS; 1-100 mm) and the Saxon test, respectively. The nizatidine and famotidine groups were compared statistically using a paired t-test.
Results: Results of the Saxon test indicated that patients receiving oral nizatidine obtained significant objective relief from their xerostomia (baseline: 0.959 ± 0.201g / 2 min; after 8 weeks of treatment: 1.334 ± 0,273g / 2 min, p<0.01). VAS scores suggested nizatidine provides mild relief of xerostomia, but the effect was not statistically significant. Salivary secretion was not increased by famotidine administration, which had no beneficial effects on the symptoms of xerostomia. Both drugs were generally well tolerated, without any adverse effects.Conclusions: Although a double-blind, controlled study would be required to confirm the efficacy of nizatidine, the present preliminary study suggests it may represent a new option for the treatment of xerostomia in SS.

 F. Shiozawa, None; K. Wakabayashi, None; T. Odai, None; T. Isozaki, None; M. Matsunawa, None; N. Yajima, None; Y. Miwa, None; M. Negishi, None; H. Ide, None; T. Kasama, None.